Novel Breast Cancer Therapies: CDK4/6 Inhibitors

STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, with 287,850 new cases and 43,250 deaths predicted to occur in 2022 (ACS, 2022). Making up 73% of cases, hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative disease is the most common subtype of breast cancer (ACS, 2019). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a novel therapeutic option for patients with HR-positive, HER2-negative advanced breast cancer. T...
i3 Health

Novel Breast Cancer Therapies: PI3K Inhibitors

STATEMENT OF NEED Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative breast cancer being the most common subtype, making up 73% of cases (ACS, 2019). In breast cancer, phosphatidylinositol-3-kinase (PI3K) overactivation is often associated with an activating mutation in the catalytic alpha subunit of PI3K (PIK3CA). These activating mutations occur in more than one third of breast cancers...
i3 Health

Advancing the Discussion and Management of Vasomotor Symptoms Associated With Menopause

Target Audience This activity has been designed to meet the educational needs of obstetrician/gynecologists (OB/GYNs), OB/GYN nurse practitioners (NPs), physician assistants (PAs) and registered nurses (RNs), as well as primary care clinicians (physicians, NPs, PAs, and RNs) who manage patients with menopause-associated vasomotor symptoms (VMS). Program Overview Are you up to date on the latest therapeutic targets for managing menopause-associated VMS? This activity will enable you to...
American Academy of CME and Spire Learning.

Hormone Sensitive Prostate Cancer " Therapeutic Approaches

TARGET AUDIENCE: This activity is designed to meet the educational needs of urologists, medical oncologists, radiation oncologists and other health care professionals responsible for treatment decisions for patients with prostate cancer. Health-care professionals may be unfamiliar with the concept of patient-centered care models that provide optimal outcomes for patients with prostate cancer. PROGRAM OVERVIEW: Module 1 covers a review of current recommendations based on NCCN guidelines for ...
Purdue University College of Pharmacy

WEBINAR: Expanding Pharmacy Proficiency in Transgender Care

Originally presented Monday, October 19, 2020 Throughout pharmacy, there have been gaps identified in the sensitivity training and literature available to pharmacy caregivers. The first half of this presentation will first provide cultural awareness and sensitivity training to improve interactions with this diverse patient population. The second half will provide education on transgender drug therapies, associated risk factors and monitoring to best serve this patient population. Pharmac...
American College of Apothecaries

Exploring Emerging Therapeutic Opportunities for Menopausal Women with Autoimmune Disease

Expert endocrinologist Ekta Kapoor, MBBS, and leading rheumatologist, Mehret Birru Talabi, MD, PhD, discuss the menopause experience for women with autoimmune conditions including the risks associated with hormone replacement therapy (HRT) in antiphospholipid (aPL)-positive patients, recommended management of vasomotor symptoms (VMS) with concomitant autoimmune diseases, and the potential with emerging neurokinin receptor antagonists in the management of VMS.

Evolving Treatment Paradigms in HR-Positive, HER2-Negative Breast Cancer: Integrating the Latest Evidence Into Clinical Practice

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Advances in therapy for patients with hormone receptor"positive (HR+)/human epidermal growth factor receptor 2"negative (HER2-) breast cancer have the potential to reduce disease recurrence and risk of mortality. However, the complex and evolving treatment landscap...
Postgraduate Institute for Medicine and RME Collaborative

Animal-Assisted Therapy and the Healing Power of Pets

This is the first course in a three part series and includes the story of Deirdre Rand’s journey with her animal companions and the lessons learned from the challenges and rewards of those relationships. Also discussed are temperament, socialization and training; the role of the neurohormone oxytocin in strengthening the human-companion animal bond; the founding of the three major organizations which register volunteer handler/therapy teams, along with the contributions of key historic figur...
Professional Development Resources

Addressing Health Care Disparities and Improving Patient Outcomes in Prostate Cancer: Expert Perspectives on Optimizing ADT

Prostate cancer is the leading cause of cancer and the second leading cause of cancer death in men in the United States. Medical androgen deprivation therapy (ADT) is the standard of care for advanced prostate cancer but may be associated with a broad range of adverse effects. Increased risk of cardiovascular (CV) events is among the most serious, as CV disease is the most common non-cancer cause of death in prostate cancer patients. Although evidence-based guidelines on ADT selection and CV r...
University of Cincinnati


CLASS OVERVIEW This CE will allow providers to gain a solid foundation regarding transgender healthcare and the skills necessary to provide healthcare for transgender patients in a safe, supportive and welcoming environment EDUCATIONAL/LEARNING OBJECTIVES: 1. Recognize and apply gender confirming and gender-nonconforming terminology to current practice 2. Review epidemiology of the LGBTQIA+ population 3. Design a welcoming, safe, and supportive environment for patients within the LGBTQI...
Western University of Health Sciences, College of Pharmacy

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map